Consensus QuidelOrtho Corporation

Equities

QDEL

US2197981051

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
38.26 ^USD	-1.16%		-10.98%	-48.09%

Apr. 02	QuidelOrtho Shares Fall on Decision to Withdraw FDA 510(k) Submission for Savanna RVP4+ Assay	MT
Apr. 02	QuidelOrtho Gets US FDA Clearance For QuickVue COVID-19 Test	MT

Evolution of the average Target Price on QuidelOrtho Corporation

Price target over the last 5 years

History of analyst recommendation changes

f4c.IobdIyXnW9gYsOxzujs8oUaCkralC4H8ybEReKL-P1s.FMitEW2kdrNZ2pYS0UgI5XbLy8XtM-KZo8QiMdO_czZh_LBSdIYcqlbK3A~a9da85008dffcaadaf03b2f2fe8178f6

Analyst Recommendations on QuidelOrtho Corporation

UBS Downgrades QuidelOrtho to Sell From Neutral, Adjusts Price Target to $42 From $70	Mar. 04	MT
William Blair Downgrades QuidelOrtho to Market Perform From Outperform	Feb. 14	MT
Citigroup Adjusts Price Target on QuidelOrtho to $50 From $72, Maintains Neutral Rating	Feb. 14	MT
Craig-Hallum Downgrades QuidelOrtho to Hold From Buy, Adjusts Price Target to $50 From $158	Feb. 14	MT
Raymond James Downgrades QuidelOrtho to Outperform From Strong Buy, Cuts Price Target to $76 From $100	Feb. 14	MT
JPMorgan Downgrades QuidelOrtho to Underweight From Neutral, Adjusts Price Target to $37 From $66	Feb. 14	MT
RBC Adjusts PT on QuidelOrtho to $81 From $130, Notes Worse-Than-Anticipated COVID Headwinds; Outperform Kept on 'Compelling' Risk/Reward	Feb. 14	MT
RBC Cuts Price Target on QuidelOrtho to $130 From $140, Keeps Outperform Rating	Dec. 21	MT
Citigroup Downgrades QuidelOrtho to Neutral From Buy, Cuts Price Target to $72 From $95	Dec. 11	MT
Raymond James Adjusts QuidelOrtho's Price Target to $110 From $130, Keeps Strong Buy Rating	23-08-15	MT
RBC Raises QuidelOrtho's Price Target to $136 From $133, Keeps Outperform Rating	23-07-17	MT
UBS Adjusts QuidelOrtho Price Target to $98 From $99, Maintains Neutral Rating	23-05-17	MT
RBC Boosts Price Target on QuidelOrtho to $133 From $130, Maintains Outperform Rating	23-05-04	MT
RBC Cuts Price Target on QuidelOrtho to $130 From $136, Maintains Outperform Rating	23-04-14	MT
RBC Cuts Price Target on QuidelOrtho to $130 From $136, Maintains Outperform Rating	23-04-13	MT
UBS Adjusts QuidelOrtho Price Target to $99 From $93, Maintains Neutral Rating	23-02-22	MT
Raymond James Cuts QuidelOrtho's Price Target to $130 From $136, Maintains Strong Buy Rating	23-02-16	MT
RBC Raises Price Target on QuidelOrtho to $136 From $125 After 'Strong' Q4, Above-Street 2023 Guidance, Maintains Outperform Rating	23-02-16	MT
Citigroup Upgrades QuidelOrtho to Buy From Neutral, Adjusts Price Target to $125 From $90	22-12-12	MT
RBC Initiates QuidelOrtho at Outperform With $125 Price Target, Sees Potential for Market Share Gains, Sales Acceleration Beyond 2024	22-12-07	MT
UBS Adjusts QuidelOrtho Price Target to $93 From $86, Maintains Neutral Rating	22-11-04	MT
UBS Upgrades QuidelOrtho to Neutral From Sell, Sets $86 Price Target	22-10-14	MT
Quidel Shares Down After Citigroup Initiates Coverage at Neutral	22-09-19	MT
Citigroup Starts Quidel at Neutral With $90 Price Target	22-09-19	MT
UBS Initiates Coverage on Quidel With Sell Rating, $86 Price Target	22-07-20	MT